Epirium Raises $85 Million in Series A Financing to Advance Unique Scientific Platform Focused on Restoration of Tissue Bioenergetics and Function
Summary
Epirium intends to advance its first clinical candidate next year, initially in Becker Muscular Dystrophy, followed by drug development targeting other progressive neuromuscular disorders associated with mitochondrial depletion. These insights opened for Epirium the door to pursue a novel and differentiated pharmacological approach for the treatment of diseases characterized by mitochondrial depletion or dysfunction leading to subsequent organ failure. “We are thrilled to partner with an exceptional team of visionary and highly respected investors, who have a strong track record in uncovering and backing only the most promising science.” said Russell Cox, President and CEO of Epirium. Despite their importance, for decades the understanding of these fundamental mechanisms needed to keep cells alive and properly functioning has lagged, resulting in a dearth of pharmacologically tractable targets. The Company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration.